Gefitinib (Iressa; AstraZeneca, London, England) has been used in the treatment of non–small cell lung cancer (NSCLC).1 The cutaneous toxic effects associated with epidermal growth factor receptor (EGFR) inhibitors are follicular eruption, paronychia, and xerosis.2-4 Herein, we describe 3 patients with reticular erythematous eruptions on the lower extremities associated with gefitinib.